|
|
||||||||
Department of Physiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8
Atrial
natriuretic peptide (ANP) exerts a chronic hypotensive effect due to a
decrease in total peripheral resistance (TPR). This study examines if
chronic ANP-dependent vasodilation is attributable to differences in
the cardiovascular regulatory activity of vascular endothelium (VE),
based on evidence that ANP affects synthesis/release and target
cardiovascular effects of endothelin-1 (ET-1), C-type natriuretic
peptide (CNP), and nitric oxide (NO). To determine if the synthetic
activity of resistance vasculature VE is chronically altered by plasma
ANP activity, we measured ET-1, CNP, and endothelial constitutive NO
synthase (ecNOS) concentration and total NOS enzyme activity in
homogenates of kidney, heart, lung, hindquarter skeletal muscle, and
brain from hypotensive transgenic mice with elevated plasma ANP,
hypertensive knockout mice (
/
) characterized by the
absence of ANP, and the corresponding normotensive wild-type (NT, +/+)
mice. Tissue distribution and abundance patterns of ET-1, CNP, ecNOS,
and NOS enzyme activity were comparable between the different genotypes
and did not differ significantly between mutant and control mice.
Antagonism of ETA/B receptors in
/
and +/+ mice in vivo with SB-209670 reduced arterial
blood pressure (ABP) significantly and comparably in both genotypes
(
27 ± 4 and
25 ± 2% change for
/
and +/+ mice, respectively) independent of any significant changes in
heart rate (HR) (
6 ± 8 and
4 ± 4% change for
/
and +/+ mice, respectively). Immunoneutralization of
CNP-specific guanylate cyclase-linked receptors (GC-B) with monoclonal
antibodies (3G12) increased ABP slightly, but not significantly, by
similar relative amounts in both
/
(10 ± 6% change)
and +/+ mice (8 ± 3% change), without changing HR significantly (4 ± 1% change for both +/+ and
/
mice). Inhibition of
NOS activity (by NG-nitro-L-arginine
methyl ester) significantly increased ABP, but the changes were
comparable between
/
(53 ± 5% change) and +/+ mice
(50 ± 6% change) and occurred in the absence of significant changes in HR (
1 ± 5 and 7 ± 5% change for
/
and +/+ mice, respectively). We conclude that the
differences in ABP associated with chronic variations in endogenous ANP
activity are not due to alterations in synthesis or responsiveness of
the cardiovascular system to the effects of ET-1, CNP, or NO.
C-type natriuretic peptide; endothelin; endothelium; nitric oxide
This article has been cited by other articles:
![]() |
J. R. Klinger, R. R. Warburton, L. Pietras, P. Oliver, J. Fox, O. Smithies, and N. S. Hill Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H58 - H65. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. MELO, M. E. STEINHELPER, S. C. PANG, Y. TSE, and U. ACKERMANN ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models Physiol Genomics, June 29, 2000; 3(1): 45 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Melo, S. C. Pang, and U. Ackermann Atrial Natriuretic Peptide: Regulator of Chronic Arterial Blood Pressure Physiology, June 1, 2000; 15(3): 143 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Ackermann and N. Azizi Increased central AT1-receptor activation, not systemic vasopressin, sustains hypertension in ANP knockout mice Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2000; 278(6): R1441 - R1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Melo, R. Agrawal, L. Zhang, M. Rezvani, A. A. Mangi, A. Ehsan, D. P. Griese, G. Dell'Acqua, M. J. Mann, J. Oyama, et al. Gene Therapy Strategy for Long-Term Myocardial Protection Using Adeno-Associated Virus-Mediated Delivery of Heme Oxygenase Gene Circulation, February 5, 2002; 105(5): 602 - 607. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |